Find, compare & contact
Alicaforsen
API Manufacturers & Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Alicaforsen API 185229-68-9?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Alicaforsen. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Alicaforsen
- Synonyms:
- Cas Number:
- 185229-68-9
- DrugBank number:
- DB06224
- Unique Ingredient Identifier:
- J8435V445B
General Description:
Alicaforsen is a chemical compound identified by the CAS number 185229-68-9. It is known for its distinct pharmacological properties and applications.
Indications:
This drug is primarily indicated for: Investigated for use/treatment in crohn's disease and ulcerative colitis. Its use in specific medical scenarios underscores its importance in the therapeutic landscape.
Mechanism of Action:
Alicaforsen functions by: Alicaforsen selectively inhibits ICAM‑1 gene expression. Over-expression of ICAM‑1 occurs in a wide variety of inflammatory disorders, including ulcerative colitis (UC), pouchitis and tissues in the eye, gastrointestinal teact, lungs and skin. UC is an inflammatory bowel disease of the colon, a part of the large intestine, and pouchitis is an inflammation of the surgically constructed internal pouch created in UC patients when their diseased colons are removed. Alicaforsen is a RNase H dependent phosphorothioate-modified antisense oligodeoxynucleotide inhibitor which shuts down specific sequences of intracellular adhesion molecule 1 (ICAM1) mRNA and thus production of ICAM1, which prevents the inflammatory response. ICAM is a cell surface glycoprotein (immunoglobulin superfamily) which facilitates leukocyte adhesion and antigen presentation in the intestinal mucosa. Alicaforsen hybridizes the oligonucleotide strand with the target mRNA to suppress expression of ICAM1. This mechanism highlights the drug's role in inhibiting or promoting specific biological pathways, contributing to its therapeutic effects.
Categories:
Alicaforsen is categorized under the following therapeutic classes: Gastrointestinal Agents, Immunologic Factors, Nucleic Acids, Nucleotides, and Nucleosides, Nucleotides, Oligonucleotides, Polynucleotides. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.
Alicaforsen is a type of Gastrointestinal Agents
Gastrointestinal Agents belong to the pharmaceutical API category that focuses on treating disorders and ailments related to the digestive system. These agents play a crucial role in addressing various gastrointestinal conditions, such as acid reflux, ulcers, irritable bowel syndrome (IBS), and inflammatory bowel disease (IBD).
One of the key types of gastrointestinal agents is proton pump inhibitors (PPIs), which work by reducing the production of stomach acid. PPIs help in treating conditions like gastroesophageal reflux disease (GERD) and peptic ulcers. Another essential class of agents is antacids, which neutralize excessive stomach acid, providing relief from heartburn and indigestion.
Gastrointestinal agents also include antispasmodics that alleviate abdominal cramps and spasms associated with conditions like IBS. These drugs work by relaxing the smooth muscles of the digestive tract. Additionally, there are drugs categorized as laxatives that aid in relieving constipation by promoting bowel movements.
Moreover, certain gastrointestinal agents act as antiemetics, effectively reducing nausea and vomiting. These drugs are particularly useful for patients undergoing chemotherapy or experiencing motion sickness.
Pharmaceutical companies develop and manufacture a wide range of gastrointestinal agents in various forms, including tablets, capsules, suspensions, and injections. These agents are typically formulated using active pharmaceutical ingredients (APIs) and other excipients to ensure their efficacy and safety.
In conclusion, gastrointestinal agents form a vital category of pharmaceutical APIs, providing relief from digestive disorders and improving overall gastrointestinal health. The availability of diverse agents catering to different conditions ensures that patients can receive targeted treatment for their specific gastrointestinal needs.
